Itano E N, Ono M A, Sumigawa M, Longo I M, Moura N C, Mendes N F
Departamento de Patologia Geral, Universidade Estadual de Londrina, Paraná, Brazil.
J Clin Lab Anal. 1991;5(3):162-7. doi: 10.1002/jcla.1860050303.
Using a polyclonal heterologous anti-soluble E-receptor serum, we identified molecules of molecular weight circa 58,000 and 150,000. The soluble receptor molecule with molecular weight of approximately 58,000 (Rs1) was initially purified from supernatant of heated lymphocytes through chromatography on Sephadex G-200 and/or DEAE-cellulose. The soluble receptor molecule with molecular weight of approximately 150,000 (Rs2) is detected at high levels in the serum of patients with cancer and uremia. Rs1 and Rs2 present in serum from cancer patients were purified by chromatography on Sephadex G-200 and by affinity chromatography using anti-Rs1 IgG. 131I-labelled supernatant of heated lymphocytes binds to sheep erythrocytes and the elution and analysis of the molecules adsorbed showed bands of molecular weights approximately 58,000 and 150,000, confirming the receptor activity of these molecules.
使用多克隆异源抗可溶性E受体血清，我们鉴定出分子量约为58,000和150,000的分子。分子量约为58,000的可溶性受体分子（Rs1）最初是通过在Sephadex G - 200和/或DEAE - 纤维素上进行色谱分离，从加热淋巴细胞的上清液中纯化得到的。分子量约为150,000的可溶性受体分子（Rs2）在癌症和尿毒症患者的血清中高水平检测到。癌症患者血清中的Rs1和Rs2通过在Sephadex G - 200上进行色谱分离以及使用抗Rs1 IgG进行亲和色谱纯化。加热淋巴细胞的131I标记上清液与绵羊红细胞结合，对吸附分子的洗脱和分析显示分子量约为58,000和150,000的条带，证实了这些分子的受体活性。
